Earnings results for Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics, Inc. is expected* to report earnings on 11/09/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 4 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.68. The reported EPS for the same quarter last year was $-0.74.
Cara Therapeutics last announced its earnings results on August 10th, 2020. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.14. The firm earned $5.63 million during the quarter, compared to the consensus estimate of $5.48 million. Cara Therapeutics has generated ($2.49) earnings per share over the last year. Cara Therapeutics has confirmed that its next quarterly earnings report will be published on Monday, November 9th, 2020. Cara Therapeutics will be holding an earnings conference call on Monday, November 9th. Interested parties can register for or listen to the call using this link.
Analyst Opinion on Cara Therapeutics (NASDAQ:CARA)
4 Wall Street analysts have issued ratings and price targets for Cara Therapeutics in the last 12 months. Their average twelve-month price target is $34.50, predicting that the stock has a possible upside of 147.31%. The high price target for CARA is $40.00 and the low price target for CARA is $30.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Cara Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $34.50, Cara Therapeutics has a forecasted upside of 147.3% from its current price of $13.95. Cara Therapeutics has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: Cara Therapeutics (NASDAQ:CARA)
Cara Therapeutics does not currently pay a dividend. Cara Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Cara Therapeutics (NASDAQ:CARA)
In the past three months, Cara Therapeutics insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $81,216.00 in company stock. Only 5.70% of the stock of Cara Therapeutics is held by insiders. 69.73% of the stock of Cara Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Cara Therapeutics (NASDAQ:CARA
Earnings for Cara Therapeutics are expected to grow in the coming year, from ($2.39) to ($2.08) per share. The P/E ratio of Cara Therapeutics is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Cara Therapeutics is -5.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Cara Therapeutics has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here